Delic Holdings (DELC.C) announced they have signed a definitive agreement to acquire Ketamine Infusion Centers (KIC). Delic will acquire all of the issued and outstanding shares of KIC from…
Biotech
“The cardinal rule is to keep them playing and to keep them coming back. The longer they play, the more they lose, and in the end, we get it…
Speed Before the widespread fear-mongering in Western media and culture around LSD it was becoming rather popular in the psychiatry community in both North America and Europe. In the…
Ortho Regenerative Technologies (ORTH.C) got some bad news today in the form of a clinical hold letter from the FDA related to their investigational new drug (IND) application fo…
Early money Earlier this week California introduced a bill to decriminalize psychedelics. If passed, SB 519 will approve the use of mushrooms, MDMA, LSD, mescaline, and ibogaine for…
The New York Times went viral (shocker) in 2015 with their article covering psychologist Arthur Aron’s study on 36 questions that lead to love. #6 is the following: “If…
COMPASS Pathways (CMPS.Q) reported further results from a Phase I study on their COMP360 psilocybin conducted at King’s College London. The study was a randomized, double-blind, placebo-controlled study intended…
Mindset Pharma (MSET.C) announced their lead clinical candidate, MSP-1014. MSP-1014 is a differentiated psilocybin-based compound from Mindset’s Family 1 of novel, patent-pending psychedelic compounds. MSET plans on moving forward…
On May 27, Delic Holdings (DELC.C) announced they have acquired all of the issued and outstanding shares in the capital of Complex Biotech Discovery Ventures (CBDV), completing their acquisition…
Cybin (CYBN.NE) announced they are sponsoring Kernel’s feasibility study of its Kernel Flow technology to measure Ketamine’s psychedelic effect on cerebral cortex hemodynamics. Cybin announced in January that they…